UROKINASE MARKET ANALYSIS

Market Challenges And Opportunities

Global Urokinase Market Drivers

The rising prevalence of pulmonary embolism globally has boosted demand for blood clot busting agents. For instance, according to National Library of Health in 2018, pulmonary embolism have high prevalence globally with 10 million cases per year. Moreover, usage of urokinase in the treatment of cardiovascular disease is also driving demand for blood clot busting agents such as urokinase. For instance, in June 2020, Hospital of Zhenghou University started clinical trial on the treatment of minor heart stroke with urokinase thrombolysis, which is expected to complete in 2021. These factors are expected to drive growth of the global urokinase market over the forecast period.

Global Urokinase Market COVID-19 Impact Analysis

Since the outbreak of COVID-19 pandemic from past year, each and every market and industry around the globe is affected in a negative way. According to American society of Hematology July 2020, 15-20% of patients suffering from acute pulmonary embolism and deep vein thrombosis require mechanical ventilation and blood clot busting agents after getting infected by COVID-19 infection. Moreover, According to World Health Organization 2019,  it is observed that COVID-19 infection leads to formation of blood clots in patients, thus there is need of blood clot busting agents, when mechanical ventilators are in shortage due to increase in patient population infected by COVID-19 infection.

Global Urokinase Market Restraints

Urokinase is contraindicated in cancer patients, as urokinase elevates plasminogen activation systems, which causes tissue invasion leading towards metastasis and causing cancer growth. Moreover, urokinase is also contraindicated in patients suffering from brain tumor and high blood pressure. These factors are expected to restrain growth of the global urokinase market.